Wednesday, October 25, 2023 9:42:38 AM
We are going to need to work thru those that bought yesterday and drove it up a dime... many will sell this morning knowing that the results have been pushed back... once that is done I would expect that the meat of that PR, the Thanksgiving time line and the presenting at the symposium* ... which specifically states they will go over the results... and as stated no one commits to going over results if they dont already know they are good...
SAN FRANCISCO, CA / ACCESSWIRE / October 25, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that on December 7, 2023, the company will present results from its pivotal Phase 3 OnTarget study of Napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the San Antonio Breast Cancer Symposium (SABCS). Napo expects to announce top line results of the trial by the Thanksgiving holiday.
Symposium: What is the simple definition of symposium?
A symposium is a conference in which experts or academics discuss a particular subject
SAN FRANCISCO, CA / ACCESSWIRE / October 25, 2023 / Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that on December 7, 2023, the company will present results from its pivotal Phase 3 OnTarget study of Napo's plant-based prescription drug crofelemer under investigation for the prophylaxis (prevention) of diarrhea associated with targeted cancer therapies used to treat solid tumors at the San Antonio Breast Cancer Symposium (SABCS). Napo expects to announce top line results of the trial by the Thanksgiving holiday.
Symposium: What is the simple definition of symposium?
A symposium is a conference in which experts or academics discuss a particular subject
Recent JAGX News
- Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates • ACCESS Newswire • 04/10/2026 12:15:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 09:04:50 PM
- Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs • ACCESS Newswire • 04/08/2026 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/07/2026 09:08:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 12:35:22 PM
- Jaguar Health Reports 2025 Financials • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/07/2026 10:10:28 AM
- Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress • ACCESS Newswire • 04/02/2026 01:00:00 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 08:19:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/24/2026 09:06:18 PM
- FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID) • ACCESS Newswire • 03/18/2026 01:00:00 PM
- Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression • ACCESS Newswire • 03/16/2026 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/13/2026 08:59:50 PM
- Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing • GlobeNewswire Inc. • 03/13/2026 12:35:00 PM
- Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts • ACCESS Newswire • 03/11/2026 01:00:00 PM
- Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th • GlobeNewswire Inc. • 03/10/2026 02:21:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/09/2026 01:05:16 PM
- Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants • ACCESS Newswire • 03/09/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2026 09:15:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 02:05:51 PM
- Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1 • ACCESS Newswire • 03/03/2026 02:00:00 PM
- Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend • ACCESS Newswire • 03/02/2026 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 02:01:37 PM
- Jaguar Health Announces a Special One-time Stock Dividend • ACCESS Newswire • 02/18/2026 02:00:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/10/2026 07:12:24 PM

